REMARKS

The "Description of the Drawings" section of the specification has been amended to place it in accordance with the formal drawings submitted in response to the Office Communication set forth by the Examiner on September 27, 2001 (Paper No. 11). No new matter is added by way of amendment.

It is not believed that extensions of time or fees for net addition of claims are required, beyond those that may otherwise be provided for in documents accompanying this paper. However, in the event that additional extensions of time are necessary to allow consideration of this paper, such extensions are hereby petitioned under 37 CFR § 1.136(a), and any fee required therefore (including fees for net addition of claims) is hereby authorized to be charged to Deposit Account No. 16-0605.

Respectfully submitted,

Eric J. Kron
Registration No. 45,941

CUSTOMER NO. 00826
ALSTON & BIRD LLP
Bank of America Plaza
101 South Tryon Street, Suite 4000
Charlotte, NC 28280-4000
Tel Raleigh Office (919) 862-2200
Fax Raleigh Office (919) 862-2260

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal service with sufficient postage as first class mail, in an envelope addressed to the Commissioner for Patents, Washington, DC 20231 on October 29, 2001.

Nora C. Martinez

Version With Markings to Show Changes Made:

Please amend the above-identified application as follows:

In the Specification:

On page 7, please replace paragraph 5 (lines 19-20) with the following paragraph:

[Figure 1] Figure 1A and 1B shows the 22438 sulfatase cDNA sequence (SEQ ID NO:2) and the deduced amino acid sequence (SEQ ID NO:1).

On page 8, please replace paragraph 2 (lines 7-8) with the following paragraph:

[Figure 5] Figure 5A, 5B and 5C shows the 23553 sulfatase cDNA sequence (SEQ ID NO:4) and the deduced amino acid sequence (SEQ ID NO:3).

On page 8, please replace paragraph 5 (lines 16-23) with the following paragraph:

[Figure 8] Figure 8A and 8B shows an analysis of the 23553 sulfatase open reading frame for amino acids corresponding to specific functional sites. For the N-glycosylation sites, the actual modified residue is the first amino acid. For protein kinase C phosphorylation sites, the actual modified residue is the first amino acid. For casein kinase II phosphorylation sites, the actual modified residue is the first amino acid. For the tyrosine kinase phosphorylation site, the actual modified residue is the last amino acid residue. For N-myristoylation sites, the actual modified residue is the first amino acid. In addition, a sulfatase signature is found from about amino acids 85-97.

On page 8, please replace paragraph 7 (lines 28-29) with the following paragraph:

[Figure 10] Figure 10A and 10B shows the 25278 sulfatase cDNA sequence (SEQ ID NO:6) and the deduced amino acid sequence (SEQ ID NO:5).

On page 9, please replace paragraph 4 (lines 21-22) with the following paragraph:

[Figure 15] Figure 15A and 15B shows the 26212 sulfatase cDNA sequence (SEQ ID NO:8) and the deduced amino acid sequence (SEQ ID NO:7).

On page 9, please replace paragraph 7 (beginning at line 29 and continuing to page 10, lines 1-6) with the following paragraph:

[Figure 18] Figure 18A and 18B shows an analysis of the 26212 sulfatase open reading frame for amino acids corresponding to specific functional sites. For the N-glycosylation sites, the actual modified residue is the first amino acid. For cAMP- and cGMP-dependent protein kinase phosphorylation sites, the actual modified residue is the last amino acid. For protein kinase C phosphorylation sites, the actual modified residue is the first amino acid. For casein kinase II phosphorylation sites, the actual modified residue is the first amino acid. For the tyrosine kinase phosphorylation site, the actual modified residue is the last amino acid residue. For N-myristoylation sites, the actual modified residue is the first amino acid. In addition, sulfatase signature sites are found from about amino acids 168-177 and 120-132.